<DOC>
	<DOCNO>NCT00993187</DOCNO>
	<brief_summary>This study assess effect sitagliptin/metformin FDC 50/1000 mg ( JanumetÂ® ) , MK-0431A ) compare effect glimepiride hemoglobin A1c ( HbA1c ) . The primary hypothesis 30 week , sitagliptin/metformin FDC 50/1000 mg provide superior reduction HbA1c ( mean change baseline ) compare glimepiride .</brief_summary>
	<brief_title>Efficacy Safety Sitagliptin/Metformin Fixed-Dose Combination ( FDC ) Compared Glimepiride Participants With Type 2 Diabetes Mellitus ( MK-0431A-202 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Has type 2 diabetes mellitus Is currently antihypoglycemic agent ( AHA ) ( least 12 week ) Visit 1/Screening Visit HbA1c great equal 7.0 % less equal 9.5 % ; currently AHA monotherapy lowdose oral combination therapy ( i.e. , less equal 50 % maximum label dose agent ) Visit 1/Screening Visit HbA1c great equal 6.5 % less equal 9.0 % Has history type 1 diabetes mellitus history ketoacidosis Has investigational approve glucagonlike peptide1 ( GLP1 ) analogue ( exenatide , liraglutide , etc . ) , investigational approve dipeptidyl peptidase IV ( DPP4 ) inhibitor ( sitagliptin , vildagliptin , alogliptin , etc . ) peroxisome proliferatoractivated receptor ( PPAR ) gamma agonist agent ( rosiglitazone , pioglitazone , etc . ) within 12 week Visit 1 Required insulin within prior 12 week Has hypersensitivity contraindication sulfonylurea medication ( glimepiride , glipizide , etc . ) , DPP4 inhibitor ( sitagliptin , vildagliptin , alogliptin , etc . ) , biguanide medication ( metformin , etc . ) Has inadequately control hypertension Has cirrhosis active liver disease Has severe cardiac condition Is obese Has human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>